$HUM: Humana Just Won Back the Star Rating It Sued Washington Over. The Market Repriced 2028 Overnight
Humana flipped 95% of its Medicare Advantage members into 4-star-plus plans for 2027, recovering the H5216 contract it sued CMS over and could not win back in court. The stock jumped ~14% premarket. We price the quality-bonus math, the Clover recalculation, and all three scenario zones.
Humana (NYSE: HUM) closed Thursday at $387.12, down on the day, and then the number that actually moves its earnings for 2028 landed after the bell. The Centers for Medicare and Medicaid Services released the final 2027 Medicare Advantage Star Ratings, and Humana announced Friday that 95% of its Medicare Advantage members are now enrolled in plans rated 4.0 stars or above for 2027, with 42% in 4.5-star plans. The stock ran roughly 14% in Friday's premarket, changing hands around $443, a level that put it above its prior 52-week high of $428.88.
For most companies on the trending list, a quality rating from a federal agency would be a footnote. For a Medicare Advantage insurer it is close to the whole ballgame. Star ratings are the mechanism through which Washington pays health plans a bonus for quality, and the difference between a 3.5-star and a 4.0-star contract is the difference between leaving a federal subsidy on the table and collecting it. Humana spent the last two years on the wrong side of that line on its single most important contract, sued the government over it, lost in court, and watched its stock get cut roughly in half from its highs as the earnings damage compounded. Friday's release is the market pricing the other direction.
The move is large because the setup was extreme. According to reporting around last year's ratings cycle, only about 20% of Humana's members sat in 4-star-or-above plans for 2026, against a weighted average rating near 3.61. Going from one-fifth to 95% of members in bonus-eligible plans is not an incremental improvement. It is a reversal of the single biggest overhang on the name, and it arrives while Humana is still growing its individual Medicare Advantage book aggressively: membership reached 6,453,700 as of June 30, up 23.4% year over year, with full-year 2026 growth guided at roughly 25%.
Why a Rating Is Worth This Much
Medicare Advantage plans are paid by the government against a county benchmark. Plans that earn 4.0 stars or higher get that benchmark raised by five percentage points, and they retain a larger share of the rebate when their bid comes in below the benchmark. That bonus money flows back into richer benefits that win enrollment, or into margin. The Kaiser Family Foundation estimated the federal government would spend more than $13 billion on Medicare Advantage quality bonus payments in 2026 alone. For an insurer with more than six million individual MA members, the swing between qualifying and not qualifying on a major contract runs into the hundreds of millions of dollars a year.
Crucially, the 2027 ratings govern the 2028 bonus year. That lag is why this is a forward-earnings event, not a current-quarter one: the ratings released this week set the quality bonus payments Humana collects in 2028, which is why the analyst community immediately repriced the out-year rather than the current quarter.
Get the next briefing free in your inbox: Join AlphaBriefing
The rest of this briefing is for paid members: the H5216 contract that drove the move and the legal fight behind it, the quality-bonus math that turns a half-star into 2028 earnings, how the Clover Health court case quietly pulled Humana across the line, what the analysts who just upgraded are actually underwriting, and scenario-by-scenario price zones now that the stock has already jumped 14%.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish, the analysis private intel clients pay four figures for, at a fraction of that.